<?xml version='1.0' encoding='utf-8'?>
<document id="32211890"><sentence text="Antiretroviral concentrations in the presence and absence of valproic acid."><entity charOffset="61-74" id="DDI-PubMed.32211890.s1.e0" text="valproic acid" /></sentence><sentence text="An unexpected drug-drug interaction has been recently reported between dolutegravir, an HIV integrase inhibitor, and valproic acid"><entity charOffset="71-83" id="DDI-PubMed.32211890.s2.e0" text="dolutegravir" /><entity charOffset="117-130" id="DDI-PubMed.32211890.s2.e1" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.32211890.s2.e0" e2="DDI-PubMed.32211890.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32211890.s2.e0" e2="DDI-PubMed.32211890.s2.e1" /></sentence><sentence text=" Despite there being several potential underlying mechanisms, plasma protein displacement has been suggested" /><sentence text=" The aim of this study was to assess plasma concentrations of several antiretrovirals when administered with or without valproic acid"><entity charOffset="120-133" id="DDI-PubMed.32211890.s4.e0" text="valproic acid" /></sentence><sentence text="" /><sentence text="We performed a therapeutic drug monitoring registry analysis and identified patients concomitantly taking antiretrovirals and valproic acid and without clinical affecting conditions or interacting drugs"><entity charOffset="126-139" id="DDI-PubMed.32211890.s6.e0" text="valproic acid" /></sentence><sentence text="" /><sentence text="One hundred and thirty-four patients were identified" /><sentence text=" Median (IQR) age and BMI were 49" /><sentence text="7 years (45-56) and 23" /><sentence text="4 kg/m2 (20" /><sentence text="8-26" /><sentence text="3) and 78 were male (58" /><sentence text="2%)" /><sentence text=" Despite small groups, we observed no major effect on antiretroviral exposure, even when considering highly protein-bound compounds (such as etravirine), with the exception of dolutegravir trough concentrations [median (IQR) = 132 ng/mL (62-227) in individuals on valproic acid versus 760 ng/mL (333-1407) in those not receiving valproic acid]"><entity charOffset="141-151" id="DDI-PubMed.32211890.s15.e0" text="etravirine" /><entity charOffset="176-188" id="DDI-PubMed.32211890.s15.e1" text="dolutegravir" /><entity charOffset="264-277" id="DDI-PubMed.32211890.s15.e2" text="valproic acid" /><entity charOffset="329-342" id="DDI-PubMed.32211890.s15.e3" text="valproic acid" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e0" e2="DDI-PubMed.32211890.s15.e0" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e0" e2="DDI-PubMed.32211890.s15.e1" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e0" e2="DDI-PubMed.32211890.s15.e2" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e0" e2="DDI-PubMed.32211890.s15.e3" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e1" e2="DDI-PubMed.32211890.s15.e1" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e1" e2="DDI-PubMed.32211890.s15.e2" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e1" e2="DDI-PubMed.32211890.s15.e3" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e2" e2="DDI-PubMed.32211890.s15.e2" /><pair ddi="false" e1="DDI-PubMed.32211890.s15.e2" e2="DDI-PubMed.32211890.s15.e3" /></sentence><sentence text="" /><sentence text="Valproic acid does not have a major effect on antiretrovirals other than dolutegravir"><entity charOffset="0-13" id="DDI-PubMed.32211890.s17.e0" text="Valproic acid" /><entity charOffset="73-85" id="DDI-PubMed.32211890.s17.e1" text="dolutegravir" /><pair ddi="false" e1="DDI-PubMed.32211890.s17.e0" e2="DDI-PubMed.32211890.s17.e0" /><pair ddi="false" e1="DDI-PubMed.32211890.s17.e0" e2="DDI-PubMed.32211890.s17.e1" /></sentence><sentence text=" The mechanism of this unexpected drug-drug interaction may be the combination of protein displacement, reduced absorption and CYP3A4 induction" /><sentence text="" /></document>